- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.06. | A vision for the future of lung cancer treatment | ||
| 30.05. | New Summit data could slow US approval plans for PD-1/VEGF drug | ||
| 30.05. | Keros lays off nearly half its staff; Astellas buys into a China biotech's ADC | ||
| 30.05. | Mixed COPD results for Regeneron, Sanofi drug cloud approval chances | ||
| 29.05. | HHS terminates Moderna contract to develop bird flu vaccine | ||
| 29.05. | Intellia filing spurs safety concerns over CRISPR drug | ||
| 29.05. | The medtech IPO window is finally open. Or is it? | ||
| 29.05. | Merck, Daiichi pull approval application for ADC in lung cancer | ||
| 28.05. | Cancer drugmaker iTeos to shut down | ||
| 28.05. | Muscle-sparing obesity drug safe for Phase 3 trial, Veru says | ||
| 28.05. | FDA leaders seek industry input on 'listening tour' | ||
| 28.05. | GSK-licensed antibiotic meets goal in late-stage study | ||
| 28.05. | GLP-1 prescriptions for weight loss soar, despite obstacles | ||
| 28.05. | [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care | ||
| 27.05. | FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots | ||
| 27.05. | Lilly to buy pain drug developer SiteOne, challenging Vertex | ||
| 27.05. | Biogen strikes RNAi deal with City; Aurion withdraws IPO | ||
| 27.05. | Patient dies in trial of Rocket gene therapy for heart condition | ||
| 27.05. | GlycoEra raises $130M, riding interest in protein degraders | ||
| 27.05. | The transformative impact of integrated informatics platforms on biopharma R&D | ||
| 27.05. | Navigating the evolving landscape of fill/finish: Challenges and what's ahead | ||
| 23.05. | FDA panel recommends keeping COVID shots targeted to same strain as last year | ||
| 22.05. | AI tool could help doctors ID breast cancers vulnerable to Enhertu | ||
| 22.05. | Zepzelca, Tecentriq combo extends survival in hard-to-treat lung cancer | ||
| 22.05. | Sanofi gains experimental Alzheimer's drug through Vigil buyout |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .